Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106031 | 0.93 | NR1I2 (0.40) | NR1I2OPRM1CYP2E1CHRM2CHRM3 | |
| SCHEMBL2106029 | 0.93 | NR1I2 (0.40) | NR1I2OPRM1CYP2E1CHRM2CHRM3 | |
| SCHEMBL2106732 | 0.89 | NR1I2 (0.42) | NR1I2OPRM1CYP2E1CHRM2CHRM3 | |
| SCHEMBL2106731 | 0.89 | NR1I2 (0.42) | NR1I2OPRM1CYP2E1CHRM2CHRM3 | |
| SCHEMBL2104870 | 0.88 | NR1I2 (0.43) | NR1I2OPRM1CYP2E1 | |
| SCHEMBL2104872 | 0.88 | NR1I2 (0.43) | NR1I2OPRM1CYP2E1 | |
| SCHEMBL2105295 | 0.88 | NR1I2 (0.41) | NR1I2CYP2E1 | |
| SCHEMBL2106524 | 0.88 | NR1I2 (0.41) | NR1I2CYP2E1 | |
| SCHEMBL2105482 | 0.88 | NR1I2 (0.41) | NR1I2CYP2E1 | |
| SCHEMBL2105297 | 0.88 | NR1I2 (0.41) | NR1I2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674118-B2 | Compounds and methods for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120164103-A1 | Compounds and Methods for the Treatment or Prevention of Flavivirus Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164103-A1 | Compounds and Methods for the Treatment or Prevention of Flavivirus Infections | ZC3HAV1, YBX1, HAX1 | NR1I2 441/4885OPRM1 2904/4885CYP2E1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.